Tigecycline-induced Pancreatitis

Lipshitz, Jay; Kruh, Jonathan N.; Cheung, Philip; Cassagnol, Manouchkathe

doi:10.1097/mcg.0b013e318164939c

Cited by 25 publications

(13 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the lack of a significant number of published cases of pancreatitis or abnormal serum amylase and lipase, Wyeth, the manufacturer of tigecycline, updated the product label to include acute pancreatitis as one of the post-marketing adverse events in July 2006 [1]. There have been three published case reports of tigecyclineinduced pancreatitis to date (Table 1) [2][3][4]. All patients reported nausea and abdominal pain following initiation of tigecycline, and the onset of acute pancreatitis was within 7-14 days.…”

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

Tigecycline-induced acute pancreatitis: case report and literature review

Hung

Kogelman

Volpe

et al. 2009

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 98%

“…Pancreatitis has been associated with tetracycline, but it was not listed as an adverse drug reaction in the product label when tigecycline was originally approved. Concerns about tigecycline-induced acute pancreatitis have recently been raised [2][3][4].…”

Section: Introductionmentioning

confidence: 99%

Tigecycline-induced acute pancreatitis: case report and literature review

Hung

Kogelman

Volpe

et al. 2009

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

“…However, its use has been limited, and the number of patients of MRSA infections receiving tigecycline has been small. In addition, cases of tigecycline-induced pancreatitis have been reported in the literature 152,153. Quinupristin-dalfopristin has been used for salvage therapy in MRSA infections in patients who are intolerant or failing standard therapy,154,155 but its use may be limited by the frequent adverse events, such as arthralgias and myalgias 156…”

Section: Hiv and Treatment Of Mrsamentioning

confidence: 99%

Methicillin-resistant Staphylococcus aureus in HIV-infected patients

Hidrón¹,

Kempker²,

Moanna³

et al. 2010

IDR

View full text Add to dashboard Cite

Concordant with the emergence of methicillin-resistant Staphylococcus aureus (MRSA) in the community setting, colonization and infections with this pathogen have become a prevalent problem among the human immunodeficiency virus (HIV)-positive population. A variety of different host- and, possibly, pathogen-related factors may play a role in explaining the increased prevalence and incidence observed. In this article, we review pathophysiology, epidemiology, clinical manifestations, and treatment of MRSA in the HIV-infected population.

show abstract

“…Pancreatitis is a well‐known adverse effect associated with tetracyclines, but it was not originally cited as an adverse event during the FDA approval process. Since then, at least six case reports of suspected tigecycline‐induced pancreatitis have been reported in the English‐language literature . Furthermore, the phase III clinical trials of tigecycline have limited external validity due to the small homogeneous patient groups tested, rendering the trials inadequate to determine rare and serious adverse events such as pancreatitis.…”

mentioning

confidence: 99%